SCD-CARRE

Website
www.scd-carre.org

The Sickle Cell Disease and Cardiovascular Risk—Red Cell Exchange (SCD-CARRE) randomized clinical trial will enroll 150 adult SCD participants in the United States and Europe to determine whether regular red blood cell exchange should be added to the current standard of care for SCD and certain characteristics. All participants will be followed on a monthly basis for one year to assess health outcomes. The SCD-CARRE trial is supported by a grant from the National Heart, Lung, and Blood Institute.